IQVIA™ Real-World Insights Bibliography

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
Affiliations(s): "1 Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel 2 Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany 3 German Centre for Diabetes Research (DZD), München-Neuherberg, Germany 4 Department of Health Service Administration, China Medical University, Taichung, Taiwan 5 Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan 6 Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan 7 Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan 8 Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan 9 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea 10 Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan 11 Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK 12 Institute of Applied Health Research, University of Birmingham, Birmingham, UK 13 Midlands Health Data Research UK, Birmingham, UK 14 DEMAND Hub, University of Birmingham, Birmingham, UK 15 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden 16 Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland 17 IQVIA Solutions Denmark A/S, Copenhagen, Denmark 18 IQVIA, Espoo, Finland 19 IQVIA, Tartu, Estonia 20 Boehringer Ingelheim International GmbH, Ingelheim, Germany 21 Boehringer Ingelheim International GmbH, US 22 Lilly Deutschland GmbH, Bad Homburg, Germany 23 Steno Diabetes Center Copenhagen, Herlev, Denmark 24 Department of Public Health, University of Copenhagen, Copenhagen, Denmark 25 Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway 26 Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway 27 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA 28 Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain"
Publication(s):  "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636 Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
Document Type(s): Article,
Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care,
  Add to report
 
 
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Author(s): Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó
Affiliations(s): "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia; b The Alfred Hospital, Melbourne, VIC, Australia; c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland; e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany; f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; i Department of Clinical Medicine, University of Bergen, Bergen, Norway; j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; l Bordeaux PharmacoEpi (BPE), Universit?e de Bordeaux, Bordeaux, France; m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA; n Global Epidemiology, IQVIA, Amsterdam, The Netherlands; o Merck Healthcare KGaA, Darmstadt, Germany"
Publication(s): 
Document Type(s): Article,
Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders,
2023
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Population Based Study,
  Add to report
 
 
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets
Author(s): Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group
Affiliations(s): 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. 2The Alfred Hospital, Melbourne, Australia. 3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France. 4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA). 5Global Database Studies, IQVIA, Tartu, Estonia. 6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands. 7IQVIA (former EPID Research), Espoo, Finland. 8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.
Publication(s):  Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977
Document Type(s): Article,
Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey,
Click here for the abstract
C:
Y:
Drug safety, Neurological disorders,
2022
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis,
  Add to report
 
 
A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab) Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries
Author(s): Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi
Affiliations(s): IQVIA, Courbevoie, France; Janssen EMEA, Medical Affairs, Italy; Janssen EMEA, Medical Affairs, UK
Publication(s):  Presented at ISPE?s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2019), August 24?28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA.
Document Type(s): Poster,
Countries: Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland,
Click here for the abstract
C:
Y:
Hematology, Oncology,
2019
  L:
A:
English
Public Health, Survey research,
  Add to report
 
 
No increased risk of spontaneous abortion and ectopic pregnancy after exposure to interferon-beta prior to or during pregnancy: Results from register-based Nordic study among women with MS
Author(s): R. Juuti1, K. M. Hakkarainen 1, S. Burkill 2, Y. Geissbuehler 3, M. Sabidó 4, C. Popescu 5, A. Adamo 6, J. Hillert 2, S. Cnattingius 2, M. Artama 7, A. Verkkoniemi-Ahola 8, K.-M. Myhr 9, J. Mehtälä 1, S. Bahmanyar 2, S. Montgomery 2,10, P. Korhonen 1 and the European Interferon Beta Pregnancy Study Group
Affiliations(s): 1StatFinn-EPID Research, Espoo, Finland
Publication(s):  EAN, Oslo, Norway, June 29-2 July, 2019
Document Type(s): Oral presentation,
Countries: Finland, Germany, Norway, Sweden, Switzerland, UK,
Click here for the abstract
C:
Y:
Neurological disorders,
2019
  L:
A:
English
Epidemiological study, Population Based Study, Retrospective database analysis,
  Add to report
 
 
Assessing the Outcomes for Orphan Status or Accelerated Assessment EMA Approved Medicines: A Comparison of Health Technology Assessment in Denmark, Finland, Norway and Sweden
Author(s): Falla, Edel; Pitcher, Ashley; Acs, Annabel; Heller, Vincent; Zhang, Rongrong
Affiliations(s): IQVIA, Real-World Insights, London, LON, UK IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Solna, AB, Sweden IQVIA, Real-World Insights, Stockholm, Sweden
Publication(s):  ISPOR Europe 2019, November 5, 2019, Copenhagen, Denmark
Document Type(s): Poster,
Countries: Denmark, Finland, Nordic, Norway, Sweden,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment,
2019
  L:
A:
English
Review,
  Add to report
 
 
Patient and caregiver indirect costs after acute cardiovascular events in Europe.
Author(s): Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5
Affiliations(s): 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium
Publication(s):  ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
Document Type(s): Oral presentation,
Countries: Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia,
Click here for the abstract
C:
Y:
Cardiovascular disease, Health economics,
2018
  L:
A:
English
Burden of illness, Cost of illness,
  Add to report
 
 
Feasibility Assessment for Conducting a Multi-Country Post-Marketing Safety Oncology Study Using Secondary Data Sources in Europe
Author(s): Wells KE, Jiang R, Tyczynski JE, Secrest M, Oliveria SA
Affiliations(s): Wells KE: IQVIA; Jiang R: Abbvie; Tyczynski JE: Abbvie; Secrest M: IQVIA; Oliveria SA: IQVIA
Publication(s):  34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Document Type(s): Abstract,
Countries: Denmark, Finland, Germany, Norway, Sweden, UK,
C:
Y:
Database Validity and methodology, Oncology, Patient Registries & Real-World Study Methods,
2018
  L:
A:
English
Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis, Review,
  Add to report
 
 
Different patterns of second?line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
Author(s): Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW
Affiliations(s): StatFinn & EPID Research, Espoo, Finland
Publication(s):  Endocrinol Diabetes Metab.
Document Type(s): Article,
Countries: Denmark, Finland, Nordic, Norway, Sweden,
Click here for the abstract
C:
Y:
Diabetes,
2018
  L:
A:
English
Population Based Study, Retrospective database analysis,
  Add to report
 
 
Predictors of Overall Survival for Multiple Myeloma Patients Depending on Transplant Status According to a Retrospective, Non-Interventional Study in Norway
Author(s): Fredrik H. Schjesvold, MD PhD, Anderson Jenna, Jaak Sõnajalg, Amy Leval, PhD, Anna Lysén, MSc, Saeeda Rana, Päivi Castren-Kortekangas, Fredrik Borgsten
Affiliations(s): Fredrik H. Schjesvold - Oslo University; Jenna Anderson - EPID Research (now part of IQVIA); Jaak Sõnajalg - EPID Research (now part of IQVIA).
Publication(s):  Blood (2018) 132 (Supplement 1): 5759.
Document Type(s): Abstract,
Countries: Norway,
Click here for the abstract
C:
Y:
Oncology,
2018
  L:
A:
English
Observational study, Population Based Study,
  Add to report
 
 
 1 of 2 Next Page Last Page